Bristol-Myers Squibb (BMY) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $2.04
- Estimate
- $1.60
- Surprise
- +27.7%
- Revenue (period 2026-06-30)
- $12.97B
- Score at report (before → after)
- 6.6 → 6.7/10
Revenue source: xbrl.
How the report landed
Bristol-Myers Squibb (BMY) beat the $1.60 estimate with adjusted EPS of $2.04 — a large 27.7% upside surprise. TrendMatrix's engine moved from Data Issue (6.6/10) to Hold at 6.7/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates BMY Buy (Wait) at 6.3/10.
4 of the last 4 quarters beat the estimate; this quarter's +27.7% surprise compares with a +12.8% four-quarter average. Next scheduled report: 2026-10-29.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.7 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Geographic: United States (69.0%)
- Thin upside margin: 4.6%
- Leverage penalty (D/E 2.0): -1.5
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $56.67
- Entry target
- $54.01
- Price target
- $59.25
- Stop
- $50.71
- Upside to target
- +4.6%
- Reward-to-risk
- 0.8:1
The stock trades at 12.7× trailing but 8.7× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-10-14 — shown for context, not personalized investment advice.
BMY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - General
- Market cap
- $117.62B
- P/E (fwd)
- 8.7
- P/E (ttm)
- 12.7
- 52-week range
- $42.52–$68.64
- Off 52-week high
- 17.4%
- RSI (14)
- 34
- Volume vs avg
- 1.17×
- Score today
- 6.3/10